Paulick Report: Medication and Performance Enhancing Drugs
in Horseracing will be in the spotlight next Thursday in Washington, D.C., when
the United States Senate's Committee on Commerce, Science and Transportation
conducts a hearing that will bring together both opponents and proponents of
the horse racing industry's current regulatory structure and permissive use of
therapeutic medication in horses, including the race-day diuretic furosemide.
The hearing is scheduled for 2:30 p.m. in the Russell
Building, Room 253. It will be lived-streamed at www.commerce.senate.gov.
This will be the second Congressional hearing in the last
three months examining drugs and horse racing. In late April, the House of
Representatives Energy and Commerce Committee's Subcommittee on Health
conducted a hearing entitled “A Review of Efforts to Protect Jockeys and Horses
in Horseracing.”
The House subcommittee included Kentucky Rep. Ed Whitfield, co-sponsor of the Interstate Horseracing Improvement Act of 2011, which would ban all drugs in a horse’s system on the day it races, require drug testing labs to meet international standards for accreditation, and impose strict penalties for rule violators.
The House subcommittee included Kentucky Rep. Ed Whitfield, co-sponsor of the Interstate Horseracing Improvement Act of 2011, which would ban all drugs in a horse’s system on the day it races, require drug testing labs to meet international standards for accreditation, and impose strict penalties for rule violators.
Sen. Tom Udall of New Mexico is a member of the Commerce
Committee and co-sponsor of the same bill.
No comments:
Post a Comment